Your browser doesn't support javascript.
loading
Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO).
Patnaik, Anup; Axford, Laura; Deng, Lin; Cohick, Evan; Ren, Xianglin; Loi, Sally; Kecman, Sam; Hollis-Symynkywicz, Micah; Harrison, Tyler J; Papillon, Julien P N; Dales, Natalie; Hamann, Lawrence G; Lee, Lac; Regard, Jean B; Marcinkeviciene, Jovita; Marro, Martin L; Patterson, Andrew W.
Affiliation
  • Patnaik A; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States. Electronic address: anup.patnaik@novartis.com.
  • Axford L; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Deng L; PK Sciences, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Cohick E; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Ren X; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Loi S; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Kecman S; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Hollis-Symynkywicz M; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Harrison TJ; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Papillon JPN; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Dales N; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Hamann LG; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Lee L; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Regard JB; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Marcinkeviciene J; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Marro ML; Cardiovascular and Metabolic Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States.
  • Patterson AW; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, United States. Electronic address: andrew.patterson@novartis.com.
Bioorg Med Chem ; 28(12): 115548, 2020 06 15.
Article in En | MEDLINE | ID: mdl-32503688
ABSTRACT
Myeloperoxidase (MPO) activity and subsequent generation of hypochlorous acid has been associated with the killing of host-invading microorganisms (e.g. bacteria, viruses, and fungi). However, during oxidative stress, high MPO activity can damage host tissue and is linked to several chronic inflammatory conditions. Herein, we describe the development of a novel biaryl, indole-pyrazole series of irreversible mechanism-based inhibitors of MPO. Derived from an indole-containing high-throughput screen hit, optimization efforts resulted in potent and selective 6-substituted indoles with good oral bioavailability and in vivo activity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peroxidase / Enzyme Inhibitors / Indoles Limits: Animals Language: En Journal: Bioorg Med Chem Journal subject: BIOQUIMICA / QUIMICA Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peroxidase / Enzyme Inhibitors / Indoles Limits: Animals Language: En Journal: Bioorg Med Chem Journal subject: BIOQUIMICA / QUIMICA Year: 2020 Document type: Article
...